Clinical trial

Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab

NCT04120753

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2019-08-26

PhasePHASE4

Study timeline

Study start (actual)2019-08-26Date precision: day

Registry last updated2024-07-01

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Hypertensionunresolved

Dyslipidemiasunresolved

Interventions

OLOMAX 20/5/5mgDRUG

OLOMAX 20/5/10mgDRUG

Olmesartan 20 mg/Amlodipine 5 mgDRUG

Sponsors & collaborators

Daewoong Pharmaceutical Co. LTD.lead sponsor

Mapped research locations

SeoulSouth Korea1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04120753 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.